Skip to main content

Table 1 Clinicopathological characteristics of patients with metastatic breast cancer, their primary tumors, and treatment

From: Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer

Characteristic Number of patients
Total number of patients 75
Age at diagnosis (years)  
   ≤50 35
   >50 40
   Range 29 to 77
Tumor size (cm)  
   <2.0 20
   ≥2.0 55
Number of positive lymph nodes  
   0 21
   1–3 21
   >3 33
Histological grade  
   1 12
   2 43
   3 20
HER2  
   Negative 63
   Positive 12
Adjuvant therapy  
   None 5
   Endocrine therapy 32
   Chemotherapy 2
   Combined 36
Disease-free interval (months)  
   Mean ± standard deviation 39.9 ± 26.4
   Median 38
   Range 1 to 123
First-line endocrine therapy  
   Tamoxifen 56
   Aromatase inhibitors 11
   LH-RH agonist 3
   LH-RH agonist + tamoxifen 4
   Fulvestrant 1
  1. LH-RH agonist, luteinizing hormone–releasing hormone agonist.